Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

97 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Hepatitis C virus recurrence after liver transplantation: a 10-year evaluation.
Gitto S, Belli LS, Vukotic R, Lorenzini S, Airoldi A, Cicero AF, Vangeli M, Brodosi L, Panno AM, Di Donato R, Cescon M, Grazi GL, De Carlis L, Pinna AD, Bernardi M, Andreone P. Gitto S, et al. Among authors: airoldi a. World J Gastroenterol. 2015 Apr 7;21(13):3912-20. doi: 10.3748/wjg.v21.i13.3912. World J Gastroenterol. 2015. PMID: 25852276 Free PMC article.
Early ribavirin treatment and avoidance of corticosteroids in hepatitis C virus (HCV)-positive liver transplant recipients: interim report of a prospective randomized trial.
Belli LS, Alberti AB, Rondinara GF, de Carlis L, Corti A, Mazza E, Airoldi A, Cernuschi A, de Gasperi A, Forti D, Pinzello GB. Belli LS, et al. Among authors: airoldi a. Transplant Proc. 2001 Feb-Mar;33(1-2):1353-4. doi: 10.1016/s0041-1345(00)02507-0. Transplant Proc. 2001. PMID: 11267324 Clinical Trial. No abstract available.
Lack of a strong association between HLA class II, tumour necrosis factor and transporter associated with antigen processing gene polymorphisms and virological response to alpha-interferon treatment in patients with chronic hepatitis C.
Airoldi A, Zavaglia C, Silini E, Tinelli C, Martinetti M, Asti M, Rossini A, Vangeli M, Salvaneschi L, Pinzello G. Airoldi A, et al. Eur J Immunogenet. 2004 Dec;31(6):259-65. doi: 10.1111/j.1365-2370.2004.00478.x. Eur J Immunogenet. 2004. PMID: 15548263
Liver transplantation for HCV cirrhosis: improved survival in recent years and increased severity of recurrent disease in female recipients: results of a long term retrospective study.
Belli LS, Burroughs AK, Burra P, Alberti AB, Samonakis D, Cammà C, De Carlis L, Minola E, Quaglia A, Zavaglia C, Vangeli M, Patch D, Dhillon A, Cillo U, Guido M, Fagiuoli S, Giacomoni A, Slim OA, Airoldi A, Boninsegna S, Davidson BR, Rolles K, Pinzello G. Belli LS, et al. Among authors: airoldi a. Liver Transpl. 2007 May;13(5):733-40. doi: 10.1002/lt.21093. Liver Transpl. 2007. PMID: 17370330 Free article.
Adverse events affect sorafenib efficacy in patients with recurrent hepatocellular carcinoma after liver transplantation: experience at a single center and review of the literature.
Zavaglia C, Airoldi A, Mancuso A, Vangeli M, Viganò R, Cordone G, Gentiluomo M, Belli LS. Zavaglia C, et al. Among authors: airoldi a. Eur J Gastroenterol Hepatol. 2013 Feb;25(2):180-6. doi: 10.1097/MEG.0b013e328359e550. Eur J Gastroenterol Hepatol. 2013. PMID: 23044808 Review.
97 results